Glenmark Pharmaceuticals has informed about press release titled ‘Glenmark Pharmaceuticals Announces Initiation of a Phase 2b Trial of GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis’.
The above information is a part of company’s filings submitted to BSE.